Jaypirca

Jaypirca is a prescription medication developed by Eli Lilly for the treatment of chronic lymphocytic leukemia (CLL). It is a BTK inhibitor that works by blocking a protein cancer cells need to grow.

Why it’s in the news: It is in the news because it has been approved by the FDA as a first-line therapy for CLL, marking a new treatment option for patients.

Latest on Jaypirca

• STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

Connections

4 entities linked to Jaypirca across the news graph.